PRESS RELEASES

Search Press Releases:
Date
Press Release
2018-03-06

TORONTO, ON, March 6, 2018 – Taiho Pharma Canada, Inc., a Canadian subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that Health Canada approved LONSURF® (trifluridine and tipiracil [as tipiracil hydrochloride] tablets) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.1

2018-01-19

Otsuka Holdings Co., Ltd. announces that it has signed the CEO Statement of Support for the Women’s Empowerment Principles (WEPs), a set of Principles focusing on corporate action to promote gender equality and women’s empowerment in the workplace, marketplace and community. The WEPs are the result of collaboration between the United Nations Global Compact (UNGC)1 and the United Nations Entity for Gender Equality and the Empowerment of Women (UN Women).2

2017-10-20

TORONTO, ON, October 20, 2017 – Taiho Pharma Canada, Inc., a Canadian subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that Health Canada accepted for review Taiho’s New Drug Submission (NDS) for trifluridine (FTD) and tipiracil (TPI), and that the NDS has been granted Priority Review status. Health Canada’s review of the NDS under Priority Review is expected to be completed in early 2018.

2019-06-07

PRINCETON, N.J., June 7, 2019 – Taiho Oncology, Inc. announces that it has assumed commercialization responsibility from Otsuka Pharmaceuticals Co., Ltd., (Otsuka) for the novel fixed-dose combination of cedazuridine and decitabine (ASTX727) and guadecitabine (SGI-110) in the U.S. and Canada, subject to regulatory approvals. Taiho Pharma Canada, Inc., will commercialize these compounds in Canada.

2019-08-19

OAKVILLE, ON, AUGUST 19, 2019 – Taiho Pharma Canada, Inc., a Canadian subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that Quebec is the first province to make LONSURF accessible with reimbursement under the Régie de l'assurance maladie du Québec (RAMQ).ii This critical listing follows a positive clinical recommendation by the Institut national d’excellence en santé et en services sociaux (INESSS) recommending that the Minister include LONSURF® (trifluridine and tipiracil [as tipiracil hydrochloride] tablets) on the List of Medications for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have failed on previous standard therapies.iii

2019-11-21

OAKVILLE, ON, Nov. 21, 2019 /CNW/ - Taiho Pharma Canada, Inc., a Canadian subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that Health Canada approved LONSURF® (trifluridine and tipiracil [as tipiracil hydrochloride] tablets) for the treatment of adult patients with metastatic gastric (stomach) cancer or adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior lines of chemotherapy including a fluoropyrimidine, a platinum, and either a taxane or irinotecan and if appropriate with HER2/neu-targeted therapy.i LONSURF received a priority review by Health Canada given the high unmet medical need in this patient population. Currently, there is no drug approved in Canada as third-line therapy for metastatic gastric or GEJ carcinoma.

2020-03-18

Colorectal Cancer Canada “Gives A Shit” about you! www.giveashitnow.ca

Montreal, Mach 2, 2020

March is Colorectal Cancer Awareness Month and what better time to support those touched by colorectal cancer and to spread the message that it is Preventable, Treatable, and Beatable!

Colorectal cancer may touch you, your family members, or a friend and it remains the second leading cause of cancer-related deaths in Canada. No matter if you are male or female, young or old, you could be at risk for colorectal cancer. One in 14 men and one in 18 women are expected to develop colorectal cancer during their lifetime. Last year alone, 26,300 Canadians were diagnosed with the disease.

Taiho Logo

Success!

Job description sent to

Success!

Event sent to

Success!

News Release sent to

You are now leaving Taiho Pharma Canada’s website.

Taiho Pharma Canada assumes no responsibility for, nor does it endorse any aspect of your use of any third party sites.

Thank you for visiting our site.

Continue